Biotech and Pharma

Eli Lilly’s Foundayo will be available to patients through the drugmaker’s online pharmacy.

Headwinds in the sector are clearing. That is good news for venture firms seeking liquidity and for a stock market looking for growth stories, Nilesh Kumar writes in a guest commentary.

It’s no secret why major drug companies are looking to smaller biotechs for growth: many pharma giants are facing looming patent expirations for blockbuster medications.

A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.

United Therapeutics stock entered Monday up 7% on the year, but moved higher on the Tyvaso drug trial results.

Lilly will obtain exclusive rights to sell treatments discovered using InSilico’s Pharma.AI model.

Technical indicators for Pfizer and GSK have turned bullish.

The key is choosing the winners from the losers by focusing on dividend coverage—the cash flow and earnings needed to cover the payouts—and the potential for improving businesses.

Sarepta Therapeutics has come under pressure following the deaths of three patients using its treatments.

The drugmaker and medical technology company sold its remaining shares in two previous partners.

The biotech company used misleading advertising to promote its flagship bladder cancer drug, the FDA concludes.

The agreement would cover the company’s Caremark pharmacy benefit manager unit, which has denied wrongdoing.

Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company.

Lilly says its experimental drug retatrutide met the primary endpoint and key secondary endpoints in a new study.

Nvidia stock pares back gains following a solid jump on the first day of the chip maker’s annual developer conference.

Eli Lilly, the maker of Zepbound and Mounjaro, faces stiff price competition in the coming year, HSBC says.

The first severe case of the virus has been detected in New York.

The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.

Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.

Adobe shares fell following the resignation of CEO Shantanu Narayen, who served in the role for nearly two decades.

From energy to supposed havens, Barron’s lays bare the economic fallout from the conflict through the following five charts

Shares in electric-vehicle makers Rivian Automotive and NIO rise following an upgrade and strong earnings, respectively.

The drug maker says its treatment of a rare kidney disease met its main goal in a late-stage trial.

The German biotech provides a weak full-year outlook and announces the exit of its co-founders.

Hims & Hers Health rallies after Novo Nordisk agrees to sell popular weight-loss drugs on its platform.